EWEdwards Lifesciences

$85.21+14% 1Y
Latest close: back above its 200-day averageOct 9, 2026what changed →

Is the business good?

Mixed

The checks split: earnings fully cash-backed (1.7×), but margins compressing.

1 good, 1 to watch, 2 neutral
Fundamental health (F-score)6 / 9SEC EDGAR · Dec 31, 2025

Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.72×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is improving vs a year ago.

Margin direction, 3 years−10.3 pts

Operating profit is falling even as sales grow, costs are outrunning the top line.

Where ROE comes from8% ROA

Margin-driven, fat margins on slower asset turns. ROE 11% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionbetter than 71% of the market
Leverage (Debt/EBITDA)top 9% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is EW?

Edwards Lifesciences earns 16% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

16%

Return on invested capital · cost of capital 9.0% · 7.4 points above what the capital costs: growth creates value

Operating margin
22%

Operating margin · Medical Devices median 2.1% · 12 months to Q2 2026

Cash conversion
1.72×

Cash conversion · 0.63× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
−1.8%

Share count, year on year · bought back, each share owns more of the company

Operating margin by fiscal year
YearOperating margin
FY202020%
FY202132%
FY202234%
FY202326%
FY202425%
FY202521%
Details›
Gross margin12 months to Q2 2026
78%
Operating margin12 months to Q2 2026
22%
Net margin12 months to Q2 2026
15%
Free cash flow margin
22%
R&D as % of revenue
17%
Revenue, trailing twelve months
$6.51B
Free cash flow, trailing twelve months
$1.43B
Net income, trailing twelve months
$1.00B
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
16%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.